Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Still a Buy?

Key Points

• Shares gapped up premarket — the stock closed at $24.61, opened at $26.42 and last traded around $27.0240 on a volume of 2,153 shares.
• Weiss Ratings upgraded the stock from a "sell (d+)" to a "hold (c-)", and the MarketBeat consensus rating is currently "Hold".
• The company reported quarterly EPS of $0.04 and revenue of $2.29 million, and the stock is trading above its 50-day simple moving average of $23.70.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $24.61, but opened at $26.42. Anbio Biotechnology shares last traded at $27.0240, with a volume of 2,153 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Anbio Biotechnology from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, February 9th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Anbio Biotechnology has an average rating of "Hold".

Anbio Biotechnology Stock Up 1.0%

The business has a 50 day simple moving average of $23.70.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last released its earnings results on Tuesday, December 30th. The company reported $0.04 earnings per share (EPS) for the quarter. The company had revenue of $2.29 million for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.